The Fundamentals of Immunotherapy in Oncology

Immunotherapy has fundamentally altered the landscape of cancer treatment. Unlike conventional therapies such as chemotherapy, radiation, or targeted therapy that directly attack cancer cells or block specific growth signals, immunotherapy harnesses the patient’s own immune system to recognize and destroy malignant cells. The immune system is naturally equipped to detect and eliminate abnormal cells, but tumors often develop sophisticated evasion mechanisms, such as expressing immune checkpoint proteins that suppress T-cell activity. Immunotherapeutic agents are designed to overcome these defenses and restore the body's natural ability to fight cancer.

The most widely used class of immunotherapy is immune checkpoint inhibitors (ICIs). These are monoclonal antibodies that block inhibitory checkpoints like PD-1, PD-L1, or CTLA-4. By releasing the brakes on T cells, ICIs enable a more robust and sustained attack against tumors. These agents have demonstrated remarkable efficacy in cancers including melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, and many others. Other forms of immunotherapy include CAR T-cell therapy, where a patient's own T cells are genetically engineered to express receptors targeting specific cancer antigens; cancer vaccines that prime the immune system against tumor-specific antigens; and oncolytic virus therapy, in which viruses are engineered to selectively infect and lyse cancer cells while simultaneously stimulating an immune response. Each modality has unique mechanisms and toxicities, but all depend on a functional, responsive immune system to be effective.

Despite transformative successes in a subset of patients, the majority of individuals do not achieve durable responses. Identifying factors that influence immunotherapy efficacy is a critical research priority. Among these factors, the metabolic health of the patient—particularly glycemic status—is emerging as a key variable. Hyperglycemia, insulin resistance, and chronic inflammation associated with diabetes can profoundly alter immune cell function, potentially undermining the very mechanisms that checkpoint inhibitors depend on for tumor control.

Diabetes: A Chronic Metabolic Disorder with Immune Implications

Diabetes mellitus, predominantly type 2 diabetes (T2D), is characterized by insulin resistance and progressive beta-cell dysfunction leading to chronic hyperglycemia. Type 1 diabetes (T1D) is an autoimmune condition in which the immune system destroys pancreatic beta cells, resulting in absolute insulin deficiency. Both forms of diabetes exert systemic effects on immune function, largely through the consequences of sustained high blood glucose. Hyperglycemia induces oxidative stress and promotes the formation of advanced glycation end-products (AGEs), which trigger a state of chronic low-grade inflammation. This inflammatory environment can impair the function of key immune cells—T cells, natural killer (NK) cells, and dendritic cells—all of which are essential for effective anti-tumor immunity.

Additionally, individuals with diabetes frequently exhibit altered gut microbiota composition, increased systemic levels of pro-inflammatory cytokines (such as TNF-α, IL-6, and IL-1β), and a higher susceptibility to infections. These factors can complicate cancer treatment and contribute to poorer outcomes. Epidemiological studies have demonstrated that diabetes is associated with an elevated risk of several malignancies, including pancreatic, liver, colorectal, breast, and bladder cancers. The underlying mechanisms are multifactorial: hyperinsulinemia promotes tumor growth via insulin-like growth factor-1 (IGF-1) receptors; chronic inflammation creates a tumor-permissive microenvironment; and obesity—a common comorbidity of T2D—amplifies systemic inflammation and insulin resistance.

Beyond cancer risk, diabetes can significantly influence the pharmacokinetics, efficacy, and toxicity of anticancer therapies. For example, patients with diabetes may be more sensitive to chemotherapy-induced peripheral neuropathy or nephrotoxicity. In the context of immunotherapy, the relationship is bidirectional: diabetes can alter the immune microenvironment and thereby affect treatment response, while ICIs can induce new-onset diabetes or worsen pre-existing glycemic control through immune-related adverse events (irAEs). This interplay makes a comprehensive understanding of both conditions essential for optimizing patient care.

Preclinical studies have elucidated several mechanisms by which hyperglycemia dampens the effectiveness of immune checkpoint inhibitors. Elevated glucose levels alter T-cell metabolism, shifting the balance from oxidative phosphorylation toward aerobic glycolysis. Glycolytic T cells have reduced proliferative capacity, diminished cytokine production, and impaired cytotoxic activity. The expression of exhaustion markers such as PD-1, TIM-3, and LAG-3 is upregulated in hyperglycemic environments, leading to a less vigorous anti-tumor response. Furthermore, hyperglycemia promotes the expansion of myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), both of which suppress anti-tumor immunity and contribute to a hostile tumor microenvironment.

Conversely, good glycemic control appears to foster a more favorable immune landscape. Animal models have shown that metformin—a first-line medication for T2D—improves T-cell function and enhances the efficacy of PD-1 blockade. Metformin reduces systemic inflammation, decreases MDSC accumulation, and modulates the composition of the gut microbiome, all of which can positively influence immunotherapy outcomes. Similar benefits have been observed with other insulin-sensitizing agents. These findings suggest that aggressive diabetes management in cancer patients may serve as a low-cost, low-toxicity adjunct to improve the response to immunotherapy.

Hyperglycemia and T-Cell Exhaustion: A Vicious Cycle

Chronic hyperglycemia not only impairs T-cell activation but also accelerates the transition to T-cell exhaustion. T-cell exhaustion is a state of progressive dysfunction characterized by reduced proliferation, cytokine production, and expression of multiple inhibitory receptors. In a diabetic milieu, glucose metabolism alters epigenetic programming in T cells, promoting a durable exhausted phenotype. This has direct implications for checkpoint inhibitor therapy: exhausted T cells are less responsive to PD-1 blockade, reducing the efficacy of such treatments. Therefore, maintaining euglycemia may help preserve T-cell fitness and prolong the duration of response to immunotherapy.

Clinical Evidence: Diabetes and Immunotherapy Response Rates

Retrospective cohort studies and meta-analyses have begun to clarify the relationship between pre-existing diabetes and outcomes in patients treated with ICIs. A 2021 meta-analysis of over 8,000 patients found that those with diabetes had a significantly higher risk of developing immune-related adverse events (irAEs) but similar overall survival compared to non-diabetic patients when treated with anti-PD-1/PD-L1 agents. However, other studies have reported worse progression-free survival and shorter duration of response in diabetic patients—particularly those with elevated baseline HbA1c or blood glucose levels. The heterogeneity of these findings highlights the need for prospective trials that carefully stratify patients by diabetes type, duration of disease, glycemic control metrics, and concomitant medications.

One notable clinical concern is the development of immune-mediated diabetes as a direct irAE. Checkpoint inhibitors—especially anti-PD-1 antibodies—can trigger rapid-onset autoimmune diabetes that often presents as fulminant type 1 diabetes with severe hyperglycemia and diabetic ketoacidosis. This is a rare but serious complication requiring immediate insulin therapy and can be life-threatening if not recognized early. Patients with pre-existing type 2 diabetes may also experience worsening glucose control during ICI therapy due to concurrent use of high-dose corticosteroids for managing other irAEs, or because of cytokine release syndrome (CRS) in the context of CAR T-cell therapy. Vigilant monitoring of blood glucose and early involvement of endocrinology are essential for managing these complexities.

Special Consideration: CAR T-Cell Therapy and Diabetes

CAR T-cell therapy, while highly effective for certain hematologic malignancies, carries a high incidence of CRS. CRS is managed with immunosuppressive agents such as tocilizumab and corticosteroids, both of which can induce hyperglycemia and exacerbate underlying diabetes. Moreover, CRS itself is associated with insulin resistance and hypermetabolic states. Therefore, close monitoring of blood glucose is essential before, during, and after CAR T-cell infusion. Many centers implement proactive insulin sliding-scale protocols and consult endocrinology early for patients with diabetes undergoing this therapy. Timely glycemic management may reduce the risk of severe infections and other complications in this vulnerable population.

Diabetes Medications as Immunotherapy Enhancers

Interest has grown in the potential of anti-diabetic agents to boost the efficacy of immunotherapy. Metformin is the most extensively studied. Beyond its glucose-lowering effects, metformin exhibits anti-inflammatory and anti-tumor properties: it inhibits the mTOR pathway, reduces oxidative stress, decreases MDSC accumulation, and favorably modifies the gut microbiome. Retrospective analyses have consistently shown that metastatic cancer patients with diabetes who take metformin have better progression-free and overall survival when treated with ICIs compared to those on other diabetes drugs. Prospective randomized trials, such as the MET-IO study, are underway to evaluate metformin as an adjunct to immunotherapy in non-diabetic patients as well.

Other classes of diabetes medications also possess immunomodulatory properties. Thiazolidinediones (e.g., pioglitazone) activate PPAR-gamma, reducing inflammation and enhancing insulin sensitivity. GLP-1 receptor agonists (semaglutide, liraglutide) lower systemic inflammation, improve endothelial function, and may enhance T-cell function. However, their role in cancer immunotherapy remains experimental and requires further study. It is equally important to avoid drugs that may impair immunity; for instance, long-term use of sulfonylureas can promote weight gain, worsen insulin resistance, and potentially blunt immune function. The choice of diabetes medication in a cancer patient should be individualized, balancing glycemic control with potential off-target immune effects, and ideally made in collaboration with an endocrinologist.

Metformin: A Potential Immune Adjuvant

A growing number of preclinical studies support the concept that metformin enhances the efficacy of checkpoint blockade. In mouse models of melanoma and colorectal cancer, metformin combined with anti-PD-1 therapy led to increased tumor infiltration by cytotoxic T cells, reduced tumor growth, and improved survival. These effects were dependent on the presence of an intact gut microbiome, suggesting a role for microbial metabolism in mediating the benefits of metformin. Clinical correlative data also indicate that metformin users have higher levels of circulating memory T cells and lower levels of pro-inflammatory cytokines. While prospective validation is needed, metformin represents a promising, inexpensive intervention to potentially augment immunotherapy responses across multiple cancer types.

Practical Management: Coordinating Diabetes and Cancer Care

Given the interplay between diabetes and immunotherapy, a multidisciplinary approach is essential. Oncologists should screen all patients for diabetes at baseline—including measurement of hemoglobin A1c and fasting blood glucose—and regularly monitor glucose levels during treatment. For patients with known diabetes, optimizing glycemic control before initiating immunotherapy may improve outcomes. The American Diabetes Association recommends a target A1c of less than 7% for most patients, but in the cancer setting, goals may be relaxed to avoid hypoglycemia, particularly if the patient has poor appetite, is receiving corticosteroids, or has significant cachexia. Individualized glucose targets are critical.

When irAEs occur—such as colitis, pneumonitis, or thyroiditis—high-dose corticosteroids are often required. This can precipitate severe hyperglycemia, necessitating insulin therapy or dose adjustments of oral agents. Oncologists should have a low threshold for consulting an endocrinologist to manage complex diabetes during irAE treatment. Similarly, patients on checkpoint inhibitors should be educated about symptoms of new-onset diabetes (excessive thirst, frequent urination, weight loss, blurred vision) and instructed to check blood glucose if symptoms arise. Early recognition of immune-mediated diabetes can prevent diabetic ketoacidosis and reduce morbidity.

Lifestyle modifications, including dietary counseling and regular physical activity, remain important for both cancer and diabetes management. Weight loss in overweight or obese patients can improve insulin sensitivity and reduce systemic inflammation. However, unintentional weight loss due to cancer cachexia requires careful monitoring and nutritional support. Diet should emphasize high fiber, lean protein, and healthy fats while limiting simple carbohydrates, but caloric intake must be sufficient to maintain immune function and prevent sarcopenia. A registered dietitian can help tailor nutritional plans to the specific needs of the patient.

Monitoring Algorithms for the Clinical Practice

Practical algorithms for monitoring glucose in patients receiving ICIs are evolving. A reasonable approach includes: (1) measurement of baseline HbA1c and random blood glucose in all patients starting immunotherapy; (2) for patients with diabetes or pre-diabetes, target a glucose level between 100-180 mg/dL prior to each treatment cycle, with more stringent targets if feasible; (3) in patients with known T1D or rapid-onset hyperglycemia, involve endocrinology early and consider continuous glucose monitoring (CGM); (4) during hospitalization for irAE management with high-dose steroids, implement insulin infusion protocols if needed; and (5) after treatment, continue periodic HbA1c checks every 3-6 months to detect late-onset immune-mediated diabetes. These steps can help reduce the impact of metabolic disturbances on cancer outcomes.

Future Directions: Personalized Medicine at the Intersection

Research is accelerating toward personalized immunotherapy strategies that incorporate a patient's metabolic status. Investigators are exploring biomarkers such as baseline C-peptide, insulin levels, and circulating inflammatory cytokines to predict which diabetic patients are most likely to benefit from ICIs. Others are examining the potential of time-restricted feeding or ketogenic diets as adjuncts to immunotherapy, based on the premise that metabolic state shapes T-cell function. Preliminary data suggest that caloric restriction or intermittent fasting may enhance immune surveillance, but prospective clinical trials are needed before these approaches can be recommended.

Another exciting area is the role of the gut microbiome. Diabetes alters the composition of gut bacteria, and a healthy microbiome is recognized as a strong enhancer of immunotherapy response. Interventions such as probiotics, prebiotics, or even fecal microbiota transplantation are being studied to "normalize" the microbiome in diabetic patients, with the goal of increasing ICI efficacy. Early-phase clinical trials are testing these concepts, and results are eagerly awaited.

Finally, the development of checkpoint inhibitors with reduced irAE profiles—or those that specifically spare endocrine organs—could benefit patients with diabetes. Novel agents such as bispecific antibodies, engineered T cells with built-in safety switches, and combination regimens designed to minimize off-target immune activation are in preclinical and clinical development. The ultimate goal is to design cancer treatment pathways that integrate optimal metabolic control, thereby maximizing the therapeutic index of immunotherapy for all patients, regardless of their glycemic status.

Biomarker-Driven Approaches

Identifying which patients with diabetes will achieve the best outcomes from immunotherapy is a priority. Some researchers propose using a composite metabolic-inflammatory score, incorporating HbA1c, a pro-inflammatory cytokine panel (e.g., IL-6, CRP, TNF-α), and gut microbiome diversity metrics. Such a score could help stratify patients and guide the use of adjunctive metabolic interventions like metformin or intensive diabetes management before and during ICI therapy. Prospective validation of these biomarkers is needed, but the potential for precision medicine at the intersection of metabolism and immunotherapy is immense.

Conclusion

The intersection of diabetes management and immunotherapy in cancer treatment is both clinically relevant and scientifically rich. Strong biological rationale and emerging clinical data support the concept that good glycemic control can enhance the immune system's ability to fight cancer and improve responses to checkpoint inhibitors. Conversely, poorly controlled diabetes may blunt immunotherapy efficacy, increase irAEs, and complicate overall management. As the population of patients living with both cancer and diabetes grows, a collaborative care model bridging oncology and endocrinology becomes essential. Ongoing research into the mechanisms linking metabolism and immunity promises to unlock new therapeutic synergies, leading to more personalized and effective treatment strategies that address the whole patient—not just the tumor.

For further reading, consider the following resources: